Taking biopharmaceutical Visterra from investment to multi-million dollar M&A

26 July 2018

On July 11, news broke of an acquisition agreement between pharmaceutical companies Visterra Inc, a Vertex Ventures HC investment, and Otsuka Pharmaceutical Co Ltd. The deal will have Japan’s Otsuka acquire Massachusetts-based Visterra for around $430M in cash by Q3 2018. We first invested in Visterra in 2014, when they visited Singapore for a Series […]

Continue Reading

Obsidian Therapeutics Announces $49.5 Million Series A Financing to Develop Controllable Cell and Gene Therapy Products

16 April 2018

Financing led by GV to focus on lead programs for next-generation oncology cell therapies Proprietary platform enables installation of pharmacologic operating systems in cell and gene therapy products to provide treating physicians with precise and dynamic control of engineered cells in patients December 06, 2017 06:15 AM Eastern Standard Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Obsidian Therapeutics, Inc., […]

Continue Reading